Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SSGJ-706 + AG
- Development stage
- Unknown
- Lead developer
- 3SBio
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
SSGJ-706 + AG is an investigational combination therapy consisting of SSGJ-706, a recombinant bispecific antibody targeting PD-1 and PD-L1, and the chemotherapy regimen AG (albumin-bound paclitaxel and gemcitabine). Developed by Sunshine Guojian Pharmaceutical, a subsidiary of 3SBio, SSGJ-706 is designed to simultaneously block two key immune checkpoints to enhance T-cell activation and anti-tumor activity. The combination with AG chemotherapy is intended to provide synergistic effects by combining immune checkpoint inhibition with cytotoxic chemotherapy. It is currently in Phase II clinical development for the treatment of advanced gastrointestinal cancers, including pancreatic ductal adenocarcinoma, gastric adenocarcinoma, and esophageal cancer.
- Other names
- SSGJ-706 plus albumin-bound paclitaxel and gemcitabineSSGJ706 plus albumin-bound paclitaxel and gemcitabineSSGJ 706 plus albumin-bound paclitaxel and gemcitabine
02
Targets
CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)PDCD1 (Programmed cell death protein 1 receptor)DNACD274 (Programmed cell death protein 1 ligand 1)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on SSGJ-706 + AG.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SSGJ-706 + AG.